These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26966023)

  • 21. Executive working memory deficits in abstinent ecstasy/MDMA users: a critical review.
    Murphy PN; Wareing M; Fisk JE; Montgomery C
    Neuropsychobiology; 2009; 60(3-4):159-75. PubMed ID: 19893333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug.
    Fox HC; Parrott AC; Turner JJ
    J Psychopharmacol; 2001 Dec; 15(4):273-81. PubMed ID: 11769821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deterioration of executive functioning in chronic ecstasy users; evidence for multiple drugs effects.
    Verbaten MN
    Curr Drug Abuse Rev; 2010 Sep; 3(3):129-38. PubMed ID: 21054259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective memory functioning among ecstasy/polydrug users: evidence from the Cambridge Prospective Memory Test (CAMPROMPT).
    Hadjiefthyvoulou F; Fisk JE; Montgomery C; Bridges N
    Psychopharmacology (Berl); 2011 Jun; 215(4):761-74. PubMed ID: 21301817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of molecular imaging of serotonin transporters in ecstasy/polydrug users.
    Roberts CA; Jones A; Montgomery C
    Neurosci Biobehav Rev; 2016 Apr; 63():158-67. PubMed ID: 26855234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired executive function in male MDMA ("ecstasy") users.
    von Geusau NA; Stalenhoef P; Huizinga M; Snel J; Ridderinkhof KR
    Psychopharmacology (Berl); 2004 Sep; 175(3):331-41. PubMed ID: 15034712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use.
    Medina KL; Shear PK
    Drug Alcohol Depend; 2007 Mar; 87(2-3):303-11. PubMed ID: 17074449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.
    Reneman L; Schilt T; de Win MM; Booij J; Schmand B; van den Brink W; Bakker O
    J Psychopharmacol; 2006 May; 20(3):389-99. PubMed ID: 16574713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.
    Wetherell MA; Montgomery C
    Psychopharmacology (Berl); 2014 Apr; 231(7):1365-75. PubMed ID: 24190587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of 'ecstasy' (MDMA) on visuospatial memory performance: findings from a systematic review with meta-analyses.
    Murphy PN; Bruno R; Ryland I; Wareing M; Fisk JE; Montgomery C; Hilton J
    Hum Psychopharmacol; 2012 Mar; 27(2):113-38. PubMed ID: 22389076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human ecstasy (MDMA) polydrug users have altered brain activation during semantic processing.
    Watkins TJ; Raj V; Lee J; Dietrich MS; Cao A; Blackford JU; Salomon RM; Park S; Benningfield MM; Di Iorio CR; Cowan RL
    Psychopharmacology (Berl); 2013 May; 227(1):41-54. PubMed ID: 23241648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
    Parrott AC
    J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users.
    Thomasius R; Petersen K; Buchert R; Andresen B; Zapletalova P; Wartberg L; Nebeling B; Schmoldt A
    Psychopharmacology (Berl); 2003 Apr; 167(1):85-96. PubMed ID: 12632248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated impulsivity and impaired decision-making in abstinent Ecstasy (MDMA) users compared to polydrug and drug-naïve controls.
    Morgan MJ; Impallomeni LC; Pirona A; Rogers RD
    Neuropsychopharmacology; 2006 Jul; 31(7):1562-73. PubMed ID: 16292322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ecstasy-related deficits in the updating component of executive processes.
    Montgomery C; Fisk JE
    Hum Psychopharmacol; 2008 Aug; 23(6):495-511. PubMed ID: 18512857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Everyday and prospective memory deficits in ecstasy/polydrug users.
    Hadjiefthyvoulou F; Fisk JE; Montgomery C; Bridges N
    J Psychopharmacol; 2011 Apr; 25(4):453-64. PubMed ID: 20123936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction.
    Quednow BB; Jessen F; Kuhn KU; Maier W; Daum I; Wagner M
    J Psychopharmacol; 2006 May; 20(3):373-84. PubMed ID: 16574711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for selective executive function deficits in ecstasy/polydrug users.
    Fisk JE; Montgomery C
    J Psychopharmacol; 2009 Jan; 23(1):40-50. PubMed ID: 18515461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for executive deficits among users of MDMA (Ecstasy).
    Fisk JE; Montgomery C; Murphy P; Wareing M
    Br J Psychol; 2004 Nov; 95(Pt 4):457-66. PubMed ID: 15527532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?
    Morgan MJ; McFie L; Fleetwood H; Robinson JA
    Psychopharmacology (Berl); 2002 Jan; 159(3):294-303. PubMed ID: 11862362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.